|
About the Pricing & Reimbursement category
|
|
0
|
33
|
February 12, 2024
|
|
First Benefit Assessment for a diagnostic agent in Germany
|
|
0
|
14
|
July 16, 2024
|
|
Dengvaxia discontinuation in the US
|
|
0
|
13
|
July 5, 2024
|
|
Use of a QoL assessment tool other than EQ-5D in the NICE submission
|
|
0
|
19
|
June 14, 2024
|
|
AMCP dossiers in the US
|
|
1
|
25
|
June 14, 2024
|
|
UK Pricing Scheme - VPAG vs VPAS
|
|
2
|
33
|
May 27, 2024
|
|
Appropriate Comparator for the GBA
|
|
1
|
35
|
May 23, 2024
|
|
Price Negotiation with the CEPS in France
|
|
1
|
60
|
May 8, 2024
|
|
Drug prices in the US
|
|
6
|
51
|
April 29, 2024
|
|
G-BA requirements for COAs
|
|
4
|
42
|
April 28, 2024
|
|
EU HTA Vaccines
|
|
1
|
37
|
April 25, 2024
|
|
Treat and Reduce Obesity Act
|
|
3
|
29
|
April 25, 2024
|
|
Inflation reduction act - prices negotiation
|
|
2
|
44
|
April 16, 2024
|
|
EU HTA scoping phase
|
|
2
|
45
|
April 13, 2024
|
|
Submission of documents on the SESAME platform
|
|
1
|
33
|
April 4, 2024
|
|
Off-label use reimbursement
|
|
5
|
83
|
March 14, 2024
|